[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence trial of dapagliflozin metformin extended-release tablets (I) in healthy Chinese participants under fasting and postprandial dosing conditions.
主要研究目的:按有关生物等效性试验的规定,选择AstraZeneca AB持证的达格列净二甲双胍缓释片(I)(商品名:Xigduo XR,规格:10mg/1000mg)为参比制剂,对双鹤天安药业(贵州)股份有限公司提供的受试制剂达格列净二甲双胍缓释片(I)(规格:10mg/1000mg)进行空腹和餐后给药人体生物等效性试验,比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内,评估两种制剂在空腹和餐后给药条件下的生物等效性。
次要研究目的:观察健康志愿试验参与者口服受试制剂达格列净二甲双胍缓释片(I)(规格:10mg/1000mg)和参比制剂达格列净二甲双胍缓释片(I)(商品名:Xigduo XR,规格:10mg/1000mg)的安全性。
[Translation] Primary Objective: In accordance with relevant bioequivalence study regulations, dapagliflozin-metformin extended-release tablets (I) (trade name: Xigduo XR, strength: 10mg/1000mg), certified by AstraZeneca AB, was selected as the reference formulation. A human bioequivalence study was conducted on the test formulation dapagliflozin-metformin extended-release tablets (I) (strength: 10mg/1000mg) provided by Shuanghe Tianan Pharmaceutical (Guizhou) Co., Ltd., under fasting and postprandial administration conditions. The study compared whether the differences in the absorption rate and extent of absorption of the drug in the test formulation with those in the reference formulation were within acceptable ranges, and evaluated the bioequivalence of the two formulations under fasting and postprandial administration conditions.
Secondary Objective: To observe the safety of oral administration of the test formulation dapagliflozin-metformin extended-release tablets (I) (strength: 10mg/1000mg) and the reference formulation dapagliflozin-metformin extended-release tablets (I) (trade name: Xigduo XR, strength: 10mg/1000mg) in healthy volunteer participants.